Induction chemotherapy before CRT improves outcomes in locally advanced cervical cancer
Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease
PROs support dostarlimab plus chemotherapy as a new standard of care in endometrial cancer
Data from selected patients in the RUBY trial show improvements in QoL domains over the course of treatment and benefits compared with placebo
Checkpoint inhibition improves outcomes in high-risk, locally advanced cervical cancer
In the KEYNOTE-A18 study, the combination of pembrolizumab and concurrent chemoradiotherapy significantly improved progression-free survival
Research promotion and good partnerships have brought rare gynaecological malignancies into the light
According to Prof. Isabelle Ray-Coquard, 2023 ESMO Awardee, the many efforts made in recent years are finally increasing treatment options for patients
First-line immunotherapy prolongs survival in advanced or recurrent endometrial cancer
Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care
Surgery remains the key to progression-free survival in ovarian sex cord-stromal tumours
Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer
What are the consequences of ‘pandemomics’ in gynaecological cancers?
As science and innovations continue to progress in gynaecological oncology, there is a need to rethink our perceptions to ensure clinical management and research advance accordingly
Is ATR inhibition a potential new treatment for rare gynaecological cancers?
Ceralasertib, alone or in combination with PARP inhibition, showed signs of clinical efficacy in patients with relapsed ovarian and endometrial clear cell carcinomas (CCC), for whom effective treatment options are currently lacking
Ovarian cancer: updated phase III data provide reassurance for the use of PARPi as maintenance therapy
Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context
Is overall survival the right endpoint for PARPi trials in ovarian cancer?
Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit